Literature DB >> 25143578

In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum β-lactamases.

Mark Estabrook1, Brianne Bussell1, Susan L Clugston2, Karen Bush3.   

Abstract

Ceftolozane MIC(50)/MIC(90)s were 4/8 μg/ml when tested against 26 CTX-M-14-type-producing isolates and 64/>64 μg/ml against 219 CTX-M-15-type-producing isolates. The addition of 4 μg/ml tazobactam lowered the ceftolozane MIC50/MIC9(0)s to ≤ 0.25/0.5 μg/ml by broth microdilution and Etest. The zone diameters for the ceftolozane-tazobactam disks were 23 to 29 mm for 92.2% of the isolates.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25143578      PMCID： PMC4313250          DOI： 10.1128/JCM.02357-14

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  23 in total

1.  Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.

Authors:  Thérèse Stachyra; Marie-Claude Péchereau; Jean-Michel Bruneau; Monique Claudon; Jean-Marie Frère; Christine Miossec; Kenneth Coleman; Michael T Black
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum beta-lactamase CTX-M-15 and of its structurally related beta-lactamase CTX-M-3.

Authors:  Laurent Poirel; Marek Gniadkowski; Patrice Nordmann
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

3.  Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).

Authors:  David J Farrell; Helio S Sader; Robert K Flamm; Ronald N Jones
Journal:  Int J Antimicrob Agents       Date:  2014-03-26       Impact factor: 5.283

4.  Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae.

Authors:  David M Livermore; Shazad Mushtaq; Yigong Ge
Journal:  J Antimicrob Chemother       Date:  2010-06-30       Impact factor: 5.790

5.  Isolation of fluoroquinolone-resistant O25b:H4-ST131 Escherichia coli with CTX-M-14 extended-spectrum β-lactamase from UK river water.

Authors:  Hiran Dhanji; Niamh M Murphy; Christine Akhigbe; Michel Doumith; Russell Hope; David M Livermore; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2010-12-15       Impact factor: 5.790

6.  Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.

Authors:  N A Kuck; N V Jacobus; P J Petersen; W J Weiss; R T Testa
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

7.  Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.

Authors:  Carlos Juan; Laura Zamorano; José L Pérez; Yigong Ge; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

8.  Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates.

Authors:  David M Livermore; Shazad Mushtaq; Yigong Ge; Marina Warner
Journal:  Int J Antimicrob Agents       Date:  2009-05-09       Impact factor: 5.283

9.  Molecular characterization and epidemiology of extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates causing health care-associated infection in Thailand, where the CTX-M family is endemic.

Authors:  Pattarachai Kiratisin; Anucha Apisarnthanarak; Chaitat Laesripa; Piyawan Saifon
Journal:  Antimicrob Agents Chemother       Date:  2008-05-27       Impact factor: 5.191

10.  Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients.

Authors:  L Naumovski; J P Quinn; D Miyashiro; M Patel; K Bush; S B Singer; D Graves; T Palzkill; A M Arvin
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191
View more
  9 in total

Review 1.  β-Lactams and β-Lactamase Inhibitors: An Overview.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

2.  A Prospective Randomized Study Comparing Ceftolozane/Tazobactam to Standard of Care in the Management of Neutropenia and Fever in Patients With Hematological Malignancies.

Authors:  Anne-Marie Chaftari; Ray Hachem; Alexandre E Malek; Victor E Mulanovich; Ariel D Szvalb; Ying Jiang; Ying Yuan; Shahnoor Ali; Rita Deeba; Patrick Chaftari; Issam Raad
Journal:  Open Forum Infect Dis       Date:  2022-02-14       Impact factor: 4.423

Review 3.  Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  David van Duin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2016-04-20       Impact factor: 9.079

Review 4.  Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections.

Authors:  Marion J Skalweit
Journal:  Drug Des Devel Ther       Date:  2015-06-04       Impact factor: 4.162

5.  Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria.

Authors:  Mark D Gonzalez; Allison R McMullen; Meghan A Wallace; Matthew P Crotty; David J Ritchie; Carey Ann D Burnham
Journal:  Ann Lab Med       Date:  2017-03       Impact factor: 3.464

6.  Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP.

Authors:  Wei Gao; Julie Passarell; Yogesh T Patel; Zufei Zhang; Gina Lin; Jill Fiedler-Kelly; Christopher J Bruno; Elizabeth G Rhee; Carisa S De Anda; Hwa-Ping Feng
Journal:  Antimicrob Agents Chemother       Date:  2022-04-26       Impact factor: 5.938

Review 7.  Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections.

Authors:  Kellie J Goodlet; David P Nicolau; Michael D Nailor
Journal:  Ther Clin Risk Manag       Date:  2016-12-01       Impact factor: 2.423

Review 8.  Production of β-Lactamase Inhibitors by Streptomyces Species.

Authors:  Daniela de Araújo Viana Marques; Suellen Emilliany Feitosa Machado; Valéria Carvalho Santos Ebinuma; Carolina de Albuquerque Lima Duarte; Attilio Converti; Ana Lúcia Figueiredo Porto
Journal:  Antibiotics (Basel)       Date:  2018-07-17

9.  Evaluation of in vitro activity of ceftolozane-tazobactam against recent clinical bacterial isolates from Brazil - the EM200 study.

Authors:  Felipe Francisco Tuon; Juliette Cieslinski; Suellen da Silva Rodrigues; Fernando Brandão Serra; Marina Della-Negra de Paula
Journal:  Braz J Infect Dis       Date:  2020-04-28       Impact factor: 3.257
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.